Zika Virus reached first time in Phase 2 trial

Zika Virus reached first time in Phase 2 trial

Overview

  • Post By : Aarti Chaturvedi
  • Source: MICROBIOZ PRESS
  • Date: 06 April, 2017

It is a type of vaccine that can protect against Zika virus It is a DNA based vaccine that reached to Phase 2 for trial.

As the Zika virus is hazardous for many countries. So our scientists had begun a trial on 29 March in Baylor College of Medicine in Houston. There were many sites where Zika virus is widespread and are involve the study like Puerto Rico, Mexico, Costa Rico, Brazil and Peru.

In Phase 2 it includes 2,400 healthy volunteers in which half will get vaccine and other will be inactive of the vaccine.

Scientists working at National Institute for Allergy and Infectious Diseases (NIAID) to see if it can provide protection against Zika virus by the end of the year, told by Dr. Anthony Fauci (Director of NIAID).

Vaccine is made from DNA genetic engineering and some proteins that are taken from Zika virus called as VRC 705. VRC 705 needs three phases of trial. Trial range depends on capability of vaccine.

In Phase 1 include 90 healthy volunteers with a pregnant woman that was started on 29 March. All of them were given this vaccine with a appropriate dose.

In Phase 2 it includes 2,400 healthy volunteers in which half will get vaccine and other will be inactive of the vaccine. Then put under observation, approximately for 2 year.

Then the result given according to the rate transmission of virus of virus and vaccine response. In later future the trial may be expanded according to its response. Trial when broaden up till 5,000 people to prove its capability. As this trial is expensive so it is funded commercially.

As the Zika virus is a member of family Flavivirus and causes disease in waves.

WHO declared that the Zika virus is no more globally hazardous. Our scientists still works as the Zika virus can continues to widespread again in future.

About Author

Aarti Chaturvedi

Aarti Chaturvedi